Today there is a lot of news one can access with regard to Roche - running the gamut from an interview with Roche CEO, Severin Schwan to their first investor's conference post-merger with Genentech to reports on their pipeline through 2014.
Mike Huckman interviewed Severin Schwan live this morning on CNBC (video).
Roche's first investor conference and webinar post-Genentech can be found here.
Finally, Reuter's reports on Roche's pipeline expectations. The company plans to launch 6 new drugs by 2014 and may have up to 35 line extensions. Drugs for diabetes and cardiovascular applications are expected to be first/best in class and blockbusters.
Posted by Bruce Lehr March 18, 2010